Core Viewpoint - The announcement by Tuoxin Pharmaceutical indicates that its subsidiary, Xinxiang Pharmaceutical, has successfully passed the GMP compliance inspections for its production facilities related to the active pharmaceutical ingredients (APIs) Olaparib and Cytidine. This compliance is expected to enhance product quality stability and production capacity, thereby supporting future business expansion [1]. Group 1: GMP Compliance - Xinxiang Pharmaceutical received two GMP compliance inspection notices from the Henan Provincial Drug Administration [1]. - The production lines for the APIs Olaparib (an anti-tumor drug) and Cytidine have met the relevant regulatory requirements [1]. - The successful GMP compliance will enable the company to better meet market demand for these pharmaceuticals [1]. Group 2: Market Impact - The API Cytidine is now ready for market sales, while Olaparib will be available after filing with the National Medical Products Administration due to a change of address [1]. - This compliance is expected to significantly boost the company's ability to ensure stable product quality and supply capacity [1].
拓新药业：原料药奥拉帕利、胞磷胆碱通过 GMP 符合性检查